drugset / Trial / NCT02300350
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple dose LX4211 (400 mg administered as 2 × 200-mg tablets qd × 12 days) on the PK of single-dose digoxin (2 × 0.25-mg tablets) in healthy male and female subjects.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | 0.5 mg | Oral |
| Subject | Sotagliflozin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.